Clinical Trials
23
Active:0
Completed:18
Trial Phases
5 Phases
Phase 1:7
Phase 2:8
Phase 3:5
+2 more phases
Drug Approvals
3
PHILIPPINES:3
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 2
8 (36.4%)Phase 1
7 (31.8%)Phase 3
5 (22.7%)Not Applicable
1 (4.5%)Phase 4
1 (4.5%)The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
Phase 3
Recruiting
- Conditions
- Idiopathic Short Stature
- Interventions
- Drug: Inpegsomatropin Injection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06927310
- Locations
- 🇨🇳
Anhui Provincial Children's Hospital, Hefei, Anhui, China
🇨🇳Gansu Provincial Maternity and Child Care Hospital, Lanzhou, Gansu, China
🇨🇳Sanya Central Hospital, Hainan, China
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06924385
- Locations
- 🇨🇳
Peking University Third Hospital, Beijin, Beijing, China
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06893796
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: ACT500 tabletsDrug: Placebo
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06716905
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Not Applicable
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06707922
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Drug Farm and Amoytop Partner on First-in-Class ALPK1 Agonist DF-006 for Hepatitis B and Liver Cancer Treatment
Drug Farm and Xiamen Amoytop Biotech have entered into an option agreement for clinical collaboration on DF-006, a first-in-class ALPK1 agonist targeting hepatitis B and hepatocellular cancer in Greater China.